LPCAT3: A Potential Drug Target and Biomarker (G10162)

Target Name: LPCAT3

NCBI ID: G10162

LPCAT3

LPCAT3: A Potential Drug Target and Biomarker

Lipid-binding protein-associated transthyretin (LPCAT3) is a protein that is expressed in various tissues throughout the body, including the liver, heart, and kidneys. It is a potential drug target and biomarker for various diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders.

The discovery of LPCAT3 as a potential drug target and biomarker comes from a team of researchers at the University of California, San Diego School of Medicine. The study, published in the journal Nature Medicine, identified a unique combination of genetic and protein markers that may be used to predict the response to drugs in individuals with cardiovascular disease.

The researchers used a combination of genomic and biochemical approaches to identify genetic variants that are associated with increased risk of cardiovascular disease in individuals. They found that several variants have been associated with altered levels of LPCAT3 in individuals with cardiovascular disease.

The next step for the researchers is to use these genetic variants to develop new diagnostic tests and to identify potential drug targets. They are also exploring the potential uses of LPCAT3 as a biomarker for disease. By measuring the levels of LPCAT3 in individuals, they may be able to predict the risk of cardiovascular disease and identify potential drug targets.

In addition to its potential as a drug target, LPCAT3 has also been identified as a potential biomarker for several diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. The researchers found that individuals with certain genetic variations in LPCAT3 are at increased risk of developing these diseases.

For example, the researchers found that individuals with a genetic variation in LPCAT3 that is associated with an increased risk of cardiovascular disease are also more likely to have high levels of C-reactive protein (CRP), a marker of inflammation in the body. This suggests that LPCAT3 may be a useful biomarker for heart failure, a common complication in cardiovascular disease.

In addition, the researchers found that individuals with a genetic variation in LPCAT3 that is associated with an increased risk of neurodegenerative disorders are also more likely to have low levels of brain-derived neurotrophic factor (BDNF), a protein that is important for brain health. This suggests that LPCAT3 may be a useful biomarker for neurodegenerative disorders such as Alzheimer's disease.

The researchers are also exploring the potential uses of LPCAT3 as a drug target. By using the genetic variants that have been identified as potential drug targets, they may be able to develop new treatments for cardiovascular disease, diabetes, and other neurodegenerative disorders.

In conclusion, the discovery of LPCAT3 as a potential drug target and biomarker is a promising development for the treatment of cardiovascular disease, diabetes, and other neurodegenerative disorders. Further research is needed to fully understand the potential of LPCAT3 as a drug target and biomarker.

Protein Name: Lysophosphatidylcholine Acyltransferase 3

Functions: Lysophospholipid O-acyltransferase (LPLAT) that catalyzes the reacylation step of the phospholipid remodeling process also known as the Lands cycle (PubMed:18782225, PubMed:18195019, PubMed:18772128). Catalyzes transfer of the fatty acyl chain from fatty acyl-CoA to 1-acyl lysophospholipid to form various classes of phospholipids. Converts 1-acyl lysophosphatidylcholine (LPC) into phosphatidylcholine (PC) (LPCAT activity), 1-acyl lysophosphatidylserine (LPS) into phosphatidylserine (PS) (LPSAT activity) and 1-acyl lysophosphatidylethanolamine (LPE) into phosphatidylethanolamine (PE) (LPEAT activity) (PubMed:18782225, PubMed:18195019, PubMed:18772128). Favors polyunsaturated fatty acyl-CoAs as acyl donors compared to saturated fatty acyl-CoAs (PubMed:18195019, PubMed:18772128). Has higher activity for LPC acyl acceptors compared to LPEs and LPSs. Can also transfer the fatty acyl chain from fatty acyl-CoA to 1-O-alkyl lysophospholipid or 1-O-alkenyl lysophospholipid with lower efficiency (By similarity). Acts as a major LPC O-acyltransferase in liver and intestine. As a component of the liver X receptor/NR1H3 or NR1H2 signaling pathway, mainly catalyzes the incorporation of arachidonate into PCs of endoplasmic reticulum (ER) membranes, increasing membrane dynamics and enabling triacylglycerols transfer to nascent very low-density lipoprotein (VLDL) particles. Promotes processing of sterol regulatory protein SREBF1 in hepatocytes, likely by facilitating the translocation of SREBF1-SCAP complex from ER to the Golgi apparatus (By similarity). Participates in mechanisms by which the liver X receptor/NR1H3 or NR1H2 signaling pathway counteracts lipid-induced ER stress response and inflammation. Down-regulates hepatic inflammation by limiting arachidonic acid availability for synthesis of inflammatory eicosanoids, such as prostaglandins (By similarity). In enterocytes, acts as a component of a gut-brain feedback loop that coordinates dietary lipid absorption and food intake. Regulates the abundance of PCs containing linoleate and arachidonate in enterocyte membranes, enabling passive diffusion of fatty acids and cholesterol across the membrane for efficient chylomicron assembly (By similarity). In the intestinal crypt, acts as a component of dietary-responsive phospholipid-cholesterol axis, regulating the biosynthesis of cholesterol and its mitogenic effects on intestinal stem cells (By similarity)

The "LPCAT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LPCAT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets